Survey of laws on new tobacco products in Latin America and the Caribbean available

The multinational tobacco companies have been aggressively promoting new tobacco products including e-cigarettes and heated tobacco products around the world. Now Eric Crosbie and his colleagues at the University of Nevada Reno and the Campaign for Tobacco Free Kids just published “New tobacco and nicotine products in Latin America and the Caribbean: assessing the marketContinue reading “Survey of laws on new tobacco products in Latin America and the Caribbean available”

Health groups raise important substantive and procedural issues with PM’s application to make reduced exposure claims for IQOS 3

The American Academy of Pediatrics, American Cancer Society Cancer Action Network, American Heart Association, American Lung Association, Campaign for Tobacco-Free Kids, and Truth Initiative have submitted a well-conceived public comment to FDA opposing Philip Morris’ request to make “modified exposure” claims about the new IQOS 3. In addition to providing important information about new studiesContinue reading “Health groups raise important substantive and procedural issues with PM’s application to make reduced exposure claims for IQOS 3”

Philip Morris ordered to suspend IQOS sales in the US

After losing a patent dispute with British American Tobacco over its IQOS heated tobacco product, Philip Morris has been forced to suspend sales of the device in the US. Specifically, BAT says that the heating element in IQOS violates a BAT patent. Philip Morris had met with the FDA and urged it to intervene withContinue reading “Philip Morris ordered to suspend IQOS sales in the US”

47 countries have banned e-cigarettes

As tobacco industry interests ramp up pressure on the WHO Framework Convention on Tobacco Control Conference of the Parties to embrace e-cigarettes and the industry’s harm reduction marketing frame, it is important to keep in mind that many countries have rejected e-cigarettes and other ENDS completely. Here is a list that Clear the Air HongContinue reading “47 countries have banned e-cigarettes”

PM’s modified risk tobacco product application for IQOS 3 ignores new published research on toxic emissions in IQOS aerosol and does not demonstrate benefits to individual or population health; FDA should deny its application to make reduced exposure claims

My UCSF TCORS colleagues and I submitted this public comment to the FDA opposing Philip Morris’ application for authorization for them to make modified risk claims for its new IQOS 3 heated tobacco product. A PDF of the comment is here. The Regulations.gov tracking number is kur-iypq-uf1v. Here is the comment: The supplemental modified riskContinue reading “PM’s modified risk tobacco product application for IQOS 3 ignores new published research on toxic emissions in IQOS aerosol and does not demonstrate benefits to individual or population health; FDA should deny its application to make reduced exposure claims”

PMPSA’s Population Health Impact Model for IQOS underestimates the health impact of IQOS, does not adequately address new published research and information on population health impacts, and does not demonstrate benefits to individual or population health, so FDA should not issue an exposure modification MRTP order for IQOS 3

My colleagues and I at the UCSF TCORS submitted this public comment to the FDA. The Regulations.gov tracking number is kta-koyn-mf7k. A PDF is available here. PMPSA’s Population Health Impact Model for IQOS underestimates the health impact of IQOS, does not adequately address new published research and information on population health impacts, and does notContinue reading “PMPSA’s Population Health Impact Model for IQOS underestimates the health impact of IQOS, does not adequately address new published research and information on population health impacts, and does not demonstrate benefits to individual or population health, so FDA should not issue an exposure modification MRTP order for IQOS 3”

PMPSA’s supplemental modified risk tobacco product application for IQOS 3 does not support the conclusion that IQOS will not harm vascular endothelial function and does not address new published research, so FDA should not issue an exposure modification MRTP order for IQOS 3 support the conclusion that IQOS will not harm vascular endothelial function and does not address new published research, so FDA should not issue an exposure modification MRTP order for IQOS 3

My colleagues and I at the UCSF TCORS just submitted this public comment to the FDA. The tracking number on Regulations.gov is kta-aq6w-3tph. A PDF is available here. PMPSA’s supplemental modified risk tobacco product application for IQOS 3 does not support the conclusion that IQOS will not harm vascular endothelial function and does not addressContinue reading “PMPSA’s supplemental modified risk tobacco product application for IQOS 3 does not support the conclusion that IQOS will not harm vascular endothelial function and does not address new published research, so FDA should not issue an exposure modification MRTP order for IQOS 3 support the conclusion that IQOS will not harm vascular endothelial function and does not address new published research, so FDA should not issue an exposure modification MRTP order for IQOS 3”

IQOS emissions create risks of immunosuppression and pulmonary toxicity and the supplemental modified risk tobacco product application for IQOS 3 does not address new published research on these risks, so FDA should not issue an exposure modification MRTP order for IQOS 3

My colleagues and I at the UCSF TCORS submitted this public comment to the FDA. The Regulations.gov tracking number is kt4-u9mw-wc65. A PDF version is available here. IQOS emissions create risks of immunosuppression and pulmonary toxicity and the supplemental modified risk tobacco product application for IQOS 3 does not address new published research on theseContinue reading “IQOS emissions create risks of immunosuppression and pulmonary toxicity and the supplemental modified risk tobacco product application for IQOS 3 does not address new published research on these risks, so FDA should not issue an exposure modification MRTP order for IQOS 3”

Youth who use heated tobacco products have a much harder time quitting cigarettes

Philip Morris won FDA authorization for its heated tobacco product (HTP) IQOS without addressing the effects it would have on youth. FDA also allowed PM to promote IQOS’ “reduced exposure” claim based on the assumption that people would “switch completely” from combusted cigarettes to IQOS. An important new study from Hong Kong draws both assumptionsContinue reading “Youth who use heated tobacco products have a much harder time quitting cigarettes”

New WHO report highlights falling cigarette use and challenges that new tobacco products pose to public health and implementation of the FCTC

On July 27, 2021 the WHO released the WHO report on the global tobacco epidemic 2021: addressing new and emerging products, its eighth such report. The good news is that it documents solid progress in reducing tobacco use. After over a century of growth, “between 2007 and 2019, smoking rates decreased from a global averageContinue reading “New WHO report highlights falling cigarette use and challenges that new tobacco products pose to public health and implementation of the FCTC”